Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study.

[1]  A. Eggermont,et al.  Synergistic antitumour effect of recombinant human tumour necrosis factor a with melphalan in isolated limb perfusion in the rat , 1996, The British journal of surgery.

[2]  A. Eggermont,et al.  Transient Induction of E‐Selectin Expression Following TNFα‐Based Isolated Limb Perfusion in Melanoma and Sarcoma Patients Is Not Tumor Specific , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[3]  F. Balkwill,et al.  Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosis. , 1995, British Journal of Cancer.

[4]  A. Eggermont,et al.  VWF release and platelet aggregation in human melanoma after perfusion with TNFα , 1995, The Journal of pathology.

[5]  F. Lejeune,et al.  High dose recombinant tumour necrosis factor (rTNF alpha) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer. , 1995, European journal of cancer.

[6]  A. Eggermont,et al.  Ischemia promotes the antitumor effect of tumor necrosis factor alpha (TNFα) in isolated limb perfusion in the rat , 1994 .

[7]  W. Martin,et al.  Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. , 1994, The Journal of pharmacology and experimental therapeutics.

[8]  A. Eggermont,et al.  Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). , 1994, International journal of cancer.

[9]  G. Grau,et al.  TNF-induced microvascular pathology: active role for platelets and importance of the LFA-1/ICAM-1 interaction. , 1993, European cytokine network.

[10]  J. Elema,et al.  A monoclonal antibody against rat platelets. I. Tissue distribution in vitro and in vivo. , 1989, Clinical and experimental immunology.

[11]  N. Bloksma,et al.  Macroscopic and microscopic early effects of tumour necrosis factor on murine Meth A sarcoma, and relation to curative activity , 1989, The Journal of pathology.

[12]  H. Kuriyama,et al.  Toxic effect of tumor necrosis factor on tumor vasculature in mice. , 1988, Cancer research.

[13]  R K Jain,et al.  Transport of molecules in the tumor interstitium: a review. , 1987, Cancer research.

[14]  A. Matter,et al.  Anti‐tumor effects of tumor necrosis factor in combination with chemotherapeutic agents , 1987, International journal of cancer.

[15]  N. Sato,et al.  Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition, and cytotoxicity. , 1986, Journal of the National Cancer Institute.

[16]  G. Wolterink,et al.  Effects of endotoxin‐treatment on inflammatory cell infiltrates in murine meth A sarcoma , 1985, The Journal of pathology.

[17]  J. Jeekel,et al.  Effect of treatment with interferon and cyclophosphamide on the growth of a spontaneous liposarcoma in rats , 1983, International journal of cancer.

[18]  W. J. van Dijk,et al.  High‐flow isolation perfusion of the rat hind limb in vivo , 1982, Journal of surgical oncology.

[19]  R. Prehn,et al.  Immunity to methylcholanthrene-induced sarcomas. , 1957, Journal of the National Cancer Institute.